Citations

Clear

4847 citation(s) found for "Tu, Eric".

Minimum clinically important difference for dysphagia after anterior cervical spine surgery using EAT-10: the peak matters
Porche, Ken, Potts, Eric A. , Foley, Kevin T., Ef, Bisson, Foley, Kevin T. , Bisson, Erica F.

Mayo Clinic

Journal of Neurosurgery: Spine | January 22, 2026 | Volume: 44 | Issue: 3 | Pages: 386-398

10.3171/2025.7.spine25551 | PMID 41569900 Get It

OBJECTIVE This study aimed to determine minimum clinically important difference (MCID) values for dysphagia using the Eating Assessment Tool-10 (EAT-10) in patients undergoing anterior cervical surgery, focusing on early dissatisfaction and later satisfaction thresholds to guide clinical decisions. METHODS Data were prospectively collected from patients undergoing anterior cervical surgery across three institutions from 2016 to 2024. Dysphagia severity was assessed preoperatively and at various postoperative stages up to 1 year using EAT-10. The inverse probability of treatment weighting was used to control for confounding variables. The retrospective study of patient data employed two analytical phases: the first phase examined the relationship between dissatisfaction at 3 months (indicated by a North American Spine Society satisfaction score > 2) and changes in EAT-10 scores from baseline to peak (i.e., worst) postoperative scores; the second phase focused on recovery, comparing changes in EAT-10 scores from peak postoperative scores to 12 months against satisfaction (score < 2) at 12 months. RESULTS The mean ± SD baseline EAT-10 score for the 1463 patients included in the study was 1.5 ± 4.7 and the mean peak score was 5.2 ± 7.4. The patients underwent anterior cervical discectomy and fusion (90%), arthroplasty (6%), or corpectomy (4%); a hybrid procedure was used in 1%. The phase 1 analysis indicated that a 4-point increase in EAT-10 score was a threshold for significant postoperative dissatisfaction in those without baseline dysphagia, with much higher thresholds observed in patients with any baseline dysphagia. In phase 2, among patients with baseline EAT-10 scores < 3 who experienced an increase to EAT-10 score ≥ 8 postoperatively, a subsequent decrease of 9 points by 12 months was necessary to report satisfaction. For patients with baseline scores 3–8 whose postoperative scores rose to ≥ 8, a subsequent decrease of 15 points was necessary for satisfaction. Patients with initial scores of ≥ 8 who did not improve to < 3 immediately after surgery required further reductions of 2–11 points to reach satisfaction. CONCLUSIONS The MCID thresholds from this study provide crucial benchmarks for assessing dysphagia changes after anterior cervical surgery, allowing tailored interventions. Patients with baseline dysphagia are less likely to experience early dissatisfaction, and high peak scores negatively impact long-term satisfaction. These findings emphasize the importance of proactive dysphagia management to enhance patient outcomes.
DOP008 Expanded Primary Analysis of the Randomized, Wait-List Controlled STOMP2 Trial Evaluating AVB-114 in Persistent Crohn’s Perianal Fistulas
Schwartz, D, Dozois, E, Ehman, Eric C. , Faubion, W, Hudesman, D, Espen, B, Pabla, Baldeep , Papadakis, K, Schwartz, David A. , Dozois, Eric J.

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.045 Get It

Abstract Background The STOMP2 trial sought to determine whether the implantable autologous cell therapy AVB-114 is an effective add-on therapy for patients with persistent Crohn’s perianal fistulas. The trial design incorporated wait-list controlled (WLC) elements, allowing eligible control group subjects who completed the 9 mo primary endpoint visit in Part 1 to request AVB-114 treatment in Part 2 and strengthen the evaluation of AVB-114’s safety and effectiveness. Methods Eligible patients had a single perianal fistula tract and had failed prior treatment or had documented medication intolerance to biologic or conventional Crohn’s disease therapy. Subjects at 14 U.S. sites were randomized 1:1 to either standard of care (SoC; fistula optimization including seton placement) or AVB-114 implantation. The primary endpoint was combined fistula remission at 9 mo, defined as no collections &gt;2cm on MRI, visual closure of the external opening, and no drainage of fluid despite gentle finger compression. A logistic regression time from exposure model through 9 mo utilized complete Part 1 data and all available Part 2 data to estimate combined AVB-114 effectiveness. Results Part 1 combined remission (using Non-Responder Imputation) was 8.3% (2/24) for SoC and 45.8% (11/24) for AVB-114 (38% difference, 95% CI 11 – 60%, post-hoc p-value of 0.0078). Twenty SoC subjects were treated with AVB-114 in Part 2. Four of the 9 Part 2 subjects with 9 mo combined remission data available were in combined fistula remission (44.4%). No subjects failed 9 mo radiological remission (first component of the primary endpoint), thus clinical remission (composite of the latter two components) was equivalent to combined remission. AVB-114 clinical remission in Part 1 and Part 2 to-date were similar, and when combined provided narrower estimates with the same coverage (Figure 1). Mean (SD) 9 mo perianal disease activity index (PDAI) scores for SoC, Part 1 AVB-114, and Part 2 AVB-114 were 5.0 (2.6), 4.1 (2.9), and 3.8 (3.5), respectively. Lower 9 mo scores and decreases from baseline were independently associated with an increased probability of clinical remission. Two serious treatment-emergent adverse events (TEAEs; pseudopolyposis and proctalgia) occurred, with the latter attributed to AVB-114. Non-serious product related TEAE were predominantly related to postoperative perianal pain. Two grade 2 (moderate) AEs of cellulitis and abdominal wall abscess were attributed to adipose tissue collection. Conclusion Both the randomized and combined (all-treated) analyses demonstrated substantial AVB-114 effectiveness through 9 mo in this challenging patient population. AEs were anticipated, and generally mild and infrequent. Conflict of interest: Schwartz, David: 1) Abbvie: consultant 2) Janssen: Consultant 3) Takeda: Consultant 4) Avbios- consultant 5) Olympus- consultant Dozois, Eric: TBD Ehman, Eric: TBD Faubion, William: TBD Hudesman, David: Consultant: Avalo, Abbvie, Abivax, Biocon, BMS, CorEvitas, Eli Lilly, Johnson and Johnson, Pfizer, Prometheus, Sanofi, Takeda, Fresenius Kabi Research Support: Pfizer and Johnson and Johnson Espen, Benjamin: employee of Avobis Bio LLC Pabla, Baldeep: Astellas, J & J - Advisory Board Prometheus - Speaker Eli Lilly - Speaker Papadakis, Konstantinos: TBD
Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection
Ghazal, Rachad , Wang, Min, Cao, Jenny Jia Ling, Vyas, Hridyanshu , Liu, Duan , Nair, Asha , Wang, Li , Yip, D., Patel, Parag C., Steidley, D. Eric , Hardaway, Brian , Clavell, Alfredo L., Kushwaha, Sudhir S. , Eisen, Howard J., Pereira, Naveen, Srinivas, Akshatha N. , Steidley, David E, Hardaway, Brian W, Pereira, Naveen L , Liu, Duan , Ghazal, Rachad , Srinivas, Akshatha N., Smith, Byron H. , Yip, Daniel , Patel, Parag C. , Clavell, Alfredo L. , Park, Walter D. , Stegall, Mark D. , Eisen, Howard J.

Mayo Clinic

Transplantation Direct | January 20, 2026 | Volume: 12 | Issue: 2 | Pages: e1882

10.1097/txd.0000000000001882 | PMID 41567756 Get It

Background. Acute cellular rejection (ACR) remains a major cause of morbidity after heart transplantation despite advances in immunosuppression. Whole genome transcriptomic profiling offers a systems-based, unbiased approach to elucidate the molecular mechanisms underlying ACR. However, noninvasive, longitudinal biomarker assessments capable of capturing the temporal dynamics of rejection biology remain scarce. Methods. RNA sequencing of peripheral blood from heart transplant recipients before, during, and after ACR was compared with nonrejection controls. Pathway analysis was conducted using differentially expressed genes (DEGs), and a machine learning approach was applied to assess gene-based prediction of ACR. Results. A total of 235 rejection-specific significant DEGs and 863 postrejection DEGs (false discovery rate < 0.05) were identified. During ACR, DEGs were enriched for T-cell activation/differentiation, apoptosis, and B-cell receptor signaling pathways. By combining the 2 sets of DEGs, a panel of 71 common genes was identified that reflected the significant, longitudinal transcriptomic dynamics of ACR. In an elastic net machine learning–based classifier, DYNLL1 and SERF2 were identified as ACR predictive genes, and achieved a cross-validated area under the receiver operating characteristic curve of 0.63. Conclusions. Peripheral blood transcriptomics identify dynamic temporal responses in ACR including T- and B-cell pathways with potential ACR predictive genes that warrant further investigation.
Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDG
Daghar, Hiba , Byeon, Seul Kee , Maios, Claudia , Poon, Jennifer Yuen Ying , Doyle, James J, Ranatunga, Wasantha , Samarut, Éric , Perlstein, Ethan , Morava, Eva, Pandey, Akhilesh , Parker, J Alex , Kantautas, Kristin A , Morava, Éva , Perlstein, Ethan O , Morava, Eva , Pandey, Akhilesh , Byeon, Seul Kee , Kantautas, Kristin A.

Mayo Clinic

No container title available | January 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.18.699766 | PMID 41648237 Get It

Abstract SRD5A3-CDG is a rare autosomal recessive congenital disorder of glycosylation characterized by multisystemic dysfunction, including neurological, psychomotor, cognitive, and visual impairments. Approximately 60 cases have been reported, with treatment limited to symptomatic management. SRD5A3 encodes a polyprenal reductase enzyme essential for synthesizing dolichol, a lipid carrier of the oligosaccharide precursor in N-glycosylation. To address the lack of effective treatments and disease models suitable for high-throughput screening, we developed the first C. elegans model of SRD5A3-CDG, harboring the homozygous W19X nonsense mutation commonly observed in patients. This model recapitulates disease-relevant phenotypes, including developmental delays, neurological dysfunction, and mevalonate pathway dysregulation. Using this model, we conducted a high-throughput motility-based drug repurposing screen and identified atorvastatin, an FDA-approved HMG-CoA reductase inhibitor, as a repurposing candidate. Atorvastatin rescued disease-relevant phenotypes in the worm model and restored polyprenol-to-dolichol ratios in patient fibroblasts. These findings highlight atorvastatin as a promising drug repurposing candidate for SRD5A3-CDG.
Amniotic Membrane (AM) Covered Airway Stent Mitigates Airway Injury and Complications
Cho, Roy Joseph , Seelig, Davis , Burroughs, Danielle, Bemenderfer, Mitchell, Tollison, Walt , Edell, Eric S. , Edell, Eric

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | January 19, 2026 | Volume: 33 | Issue: 2 | Pages: No page available

10.1097/lbr.0000000000001052 | PMID 41549996 Get It

Background: Airway stenting is a critical intervention to restore airway patency, yet complications such as stent migration, mucostasis, airway injury, and granulation tissue formation remain major concerns. Although various covering materials have been explored, the effectiveness of amniotic membrane (AM) as a stent cover has not been evaluated. This study is the first to assess airway-related complications of a novel AM-covered self-expandable metallic stent (SEMS) compared with a commercially available synthetic polymer-covered SEMS. To compare the incidence of stent-related complications between AM-covered SEMS and synthetic polymer-covered SEMS over a 90-day in vivo survival period. Methods: Eight adult Yucatan miniswine were implanted with either an AM-covered or control stent and monitored over 90 days with bronchoscopic evaluations at 4 timepoints. Histologic assessments were performed at termination. Results: Seven animals completed the study (4 AM stents, 3 controls). One control animal was terminated early due to stent expectoration. AM-covered stents were associated with reduced stent migration, mucostasis, and granulation tissue formation compared with controls. Histologic analysis revealed significantly less airway injury and evidence of re-epithelialization with cilia in the AM group; a feature absent in control stents. One animal was excluded at implantation and replaced due to a procedural complication unrelated to the stent. Conclusion: This is the first study to evaluate stent-related complications of AM-covered airway stents. The results demonstrate that AM-covered SEMS reduce airway injury and common complications associated with synthetic polymer-covered stents. These findings suggest that AM-coverings may enhance biocompatibility and integration while mitigating adverse airway responses. Larger studies and human clinical trials are needed to validate these results and explore clinical application.
Optimizing Control Definitions in Opioid Use Disorder Genetic Research Using Electronic Health Records
Niarchou, Maria , Tsai, Ellen , Jennings, Mariela, Faucon, Annika, Lee, Hyunjoon, Tubbs, Justin D. , Roussos, Panos, Ge, Tian, Crist, Richard C. , Vickers‐Smith, Rachel, Edenberg, Howard, Moore, Amy, Webb, Bradley T. , Johnson, Eric, Workgroup, PsycheMERGE Substance Use Disorder, Smoller, Jordan W., Davis, Lea K., Coombes, BJ, Voloudakis, Georgios, Burstein, David , Mallard, TT, Troiani, Vanessa , Sanchez‐Roige, Sandra, Roussos, Panos , Johnson, Eric O. , Tsai, Ellen L , Tubbs, Justin D , Roussos, Panagiotis , Ge, Tian , Crist, Richard C , Vickers-Smith, Rachel , Moore, Amy , Johnson, Eric O , Kember, Rachel L , Voloudakis, Georgios , Burstein, David , Troiani, Vanessa , Sanchez-Roige, Sandra , Faucon, Annika B. , Singh, Kritika , Kember, Rachel L. , Smoller, Jordan W. , Davis, Lea Karatheodoris , Voloudakis, Georgios , Mallard, Travis T.

Mayo Clinic

Addiction Biology | January 19, 2026 | Volume: 31 | Issue: 1 | Pages: No page available

10.1111/adb.70094 | PMID 41549723 Get It

ABSTRACT Amidst the opioid crisis, understanding the genetic basis of opioid use disorder (OUD) is crucial for identifying biological mechanisms and intervention points. However, genome‐wide association studies (GWASs) have been hampered by inadequate sample sizes and often the use of control populations not assessed for prior opioid exposure. Because opioid exposure is a prerequisite for the development of OUD, consideration of exposure history in controls is important. Electronic health record data (EHR) paired with genomic information allow a broader sampling of patients with OUD and exposed controls. We leveraged data across two healthcare systems to evaluate the impact of using controls not screened for opioid exposure (‘generic’) versus minimally opioid‐exposed control (‘exposed’). First, at the phenotypic level, we conducted phenome‐wide association studies (PheWAS) to compare the medical comorbidity profiles of OUD cases when using generic versus exposed controls. While PheWAS results for OUD‐related comorbidities were more pronounced when using the generic group, 83% of the disease associations were overlapping and of similar effect sizes. Second, at the genetic level, we conducted GWAS (cases vs. generic; cases vs. exposed) and assessed differences in genetic correlations and degrees of phenotypic misclassification. Genetic results were concordant across control groups based on heritability (generic: 0.16 ± 0.07 vs. 0.10 ± 0.07), associations with the coding OPRM1 variant rs1799971 ( p generic = 8.83E‐03 vs. p exposed = 1.83E‐02) and genetic correlations with prior OUD GWAS ( r g‐generic = 0.83 ± 0.26 vs. r g‐exposed = 0.78 ± 0.27). Although GWASs were limited by sample size ( N generic = 6269, N exposed = 6365), compared to an independent OUD GWAS ( N = 425 944), the dilution value for the two GWAS was not different from 1, suggesting no major impact of phenotypic misclassification. This study represents the first effort to enhance OUD genetic research through optimization of control definitions using EHR data. Generic controls ascertained within the US health systems, where exposure to prescription opioids is high, offer a practical alternative for genetic studies of OUD.
Endoscopic Sampling Impact on PICaSSO Histologic Remission Index Scoring in Ulcerative Colitis
Imhoff, Mackenzie E. C., Parecki, Genevieve , Bowen, Rachel, Zhao, Xiaoxian X., Moses, Richard E., Gui, Xianyong, Ballard, Darryl, Abiera, Via S, Lu, Haiyan, Sticker, Adriaan , Gruver, Aaron M. , Imhoff, Mackenzie E.C. , Holzer, Timothy R. , Hsi, Eric D. , Moses, Richard , Gui, Xianyong, Koch, Alexander , Credille, Kelly M.

Mayo Clinic

JCC Plus | January 17, 2026 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/jcc5.70008 Get It

ABSTRACT Background Despite histologic remission (HR) being important in management of ulcerative colitis, the impact of endoscopic sampling on newer scoring systems remains uncertain. This study examines the outcome of applying PICaSSO Histologic Remission Index (PHRI) scoring on biopsies collected during routine clinical care and investigates the impact of endoscopic sampling variation on PHRI scoring and HR status. Methods A retrospective survey of UC endoscopic biopsies ( N = 128, 559 bites, 1–13 bites/biopsy) was evaluated using standard H&E stain and myeloperoxidase (MPO) immunohistochemistry to aid neutrophil identification. Convolutional neural networks (CNN), trained on colonic tissue architecture and cytomorphology features, were deployed alongside pathologist interpretations. In silico modeling of bite‐derived virtual biopsies ( N = 19,760) was investigated to determine the impact of sampling variation on PHRI scores and compared with ground truth clinical samples. Results PHRI MPO scoring displayed improved sensitivity and specificity for identifying neutrophils, compared with PHRI H&E . CNN‐derived PHRI scoring was most accurate for chronic active and chronic active with ulceration categories, with greatest variability observed in chronic inactive biopsies. Virtual patient biopsies comprised of < 5 endoscopic bites were impacted most by sampling permutations. Limited variability in PHRI scores was observed in samples consisting of ≥ 5 bites. Conclusions HR status (PHRI = 0) determination was slightly impacted by sampling. Biopsies consisting of < 5 endoscopic bites exhibited the most variability. Conservative sampling of 5–7 endoscopic bites may produce more accurate assessments of microscopic heterogeneity in clinical studies employing quantitative histologic measurements to assess disease activity and remission. Additionally, incorporating MPO increased the sensitivity and specificity of detecting active inflammation for PHRI scoring.
Research Code Sharing in Support of Gold Standard Science
Klonoff, David C., Espinoza, Juan, Mader, Julia K., Heinemann, Lutz, Cobelli, Claudio, Kerr, David , Kovatchev, Boris, Najafi, Bijan , Prahalad, Priya , Zheng, Yaguang , Shao, Mandy M. , Scheideman, Agatha F. , DuNova, Ashley Y. , Kohn, Michael , Umpierrez, Guillermo E., Malek, Aiman Abdel, Agus, Michael S. D., Ahn, David T., AlSaad, Rawan , AL-SOFIANI, MOHAMMED, Armstrong, David, Arnold, Mark A., Bequette, B. Wayne , Bellazzi, Riccardo, Cengiz, Eda, Chase, J. Geoffrey, Chen, Jake Y. , Cichosz, Simon Lebech , Clements, Mark A. , Close, Kelly L., Cuadros, Jorge , Contreras, Ivan, Drincic, Andjela , Facchinetti, Andrea, Fleming, G. Alexander , Gabbay, Monica A. L., Healey, Elizabeth, Hoang, Thanh D., Kulzer, Bernhard, Belle, Jeff La, Lee, Aaron, Lee, Cecilia S., Lee, Wei-An , Liepmann, Dorian , Maahs, David M. , Mathioudakis, Nestoras, Metwally, Ahmed A., Mohan, Viswanathan, Moon, Sun-Joon, Raeder, Helge, Rhee, Connie, Rhee, Eun-Jung, Scheinker, David , Shah, Viral N., Snyder, Michael P., Sode, Koji, Spanakis, Elias K., Svensson, Jannet, Vaswani, Nitin, Vareth, Maryam, Wallia, Amisha , Wang, Tao, Williams, Ebonie, Wolf, Ruth, Wong, Jenise C., Yeshiwas, Sewagegn, Shah, Shahid N. , Cobelli, Claudio , Snyder, M , Kovatchev, Boris , Heinemann, Lutz , Espinoza, Juan , Mathioudakis, Nestoras , Mader, Julia K. , Klonoff, David C , Espinoza, Juan , Mader, Julia K , Heinemann, Lutz , Cobelli, Claudio , Kovatchev, Boris , Umpierrez, Guillermo E. , Wong, Tien Y , Abdel Malek, Aiman , Agus, Michael S D , Ahn, David T , AlSaad, Rawan , Al-Sofiani, Mohammed E , Armstrong, David , Arnold, Mark A , Bee, Yong Mong , Bequette, B Wayne , Bellazzi, Riccardo , Cengiz, Eda , Chase, James Geoffrey , Chen, Haipeng , Chen, Jake Y , Cichosz, Simon L , Cinar, Ali , Clements, Mark A , Close, Kelly L , Cuadros, Jorge , Contreras, Ivan , Datta, Gora , Dhatariya, Ketan , Doyle, Francis J , Drincic, Angela , Facchinetti, Andrea , Fleming, G Alexander , Foreman, Joshua , Gabbay, Monica A L , Gutierrez-Osuna, Ricardo , Healey, Elizabeth , Hoang, Thanh D , Jacobs, Peter G , Kulzer, Bernhard , La Belle, Jeff , Lee, Aaron Y , Lee, Cecilia S , Lee, Wei-An Andy , Liepmann, Dorian , Maahs, David M , Mathioudakis, Nestoras N , Meo, Sultan A , Metwally, Ahmed A , Misra, Shivani , Mohan, Viswanathan , Moon, Sun-Joon , Raeder, Helge , Rhee, Connie M , Rhee, Eun-Jung , Scheinker, David , Shah, Viral N , Sheng, Bin , Snyder, Michael , Sode, Koji , Spanakis, Elias K , Svensson, Jannet , Vaswani, Nitin , Vareth, Maryam , Vehi, Josep , Wallia, Amisha , Waki, Kayo , Wang, Tao , Williams, Eric , Wolf, Risa M , Wong, Jenise C , Bekele, Sewagegn Yeshiwas , Zilbermint, Mihail , Shah, Shahid N , Klonoff, David C. , DuBord, Ashley Y., Wong, Tien Yin , Agus, Michael S. D. , Ahn, David , Close, Kelly L. , Dhatariya, Ketan , Doyle, Francis J. , Rhee, Connie M. , Sode, Koji , Spanakis, Elias K. , Waki, Kayo , Wong, Jenise C. , Zilbermint, Mihail

Mayo Clinic

Journal of Diabetes Science and Technology | January 14, 2026 | Volume: 20 | Issue: 3 | Pages: 609-619

10.1177/19322968251391819 | PMID 41532590 Get It

Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.
Evoked connectivity of cortical stimulation for memory
Cole, Eric R. , DeHaan, Riley D. , Blanpain, Lou T, Sakon, John J. , Sheth, Sameer, Sperling, Michael, Lega, Bradley, Worrell, Greg, Kahana, Michael J. , Blanpain, Lou T. , Laxpati, Nealen G. , Sheth, Sameer A. , Zaghloul, Kareem A. , Jobst, Barbara C. , Sperling, Michael R. , Lega, Bradley Charles , Worrell, Gregory A. , Gross, Robert E.

Mayo Clinic

No container title available | January 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.10.26343861 Get It

Abstract Despite promising results, it remains unclear how to optimally target and personalize closed-loop stimulation to ameliorate deficits in memory and other cognitive functions. We hypothesized that evoked connectivity – the measurement of neural pathway activation using single pulses of electrical stimulation – can guide patient-specific selection of stimulation location and parameters for memory. We characterized brain-wide evoked connectivity profiles of stimulation in memory-related brain regions recorded from 81 patients undergoing intracranial monitoring for epilepsy, showing that greater evoked connectivity between the lateral temporal cortex and the broader memory network (including the mesial temporal lobe, limbic regions and prefrontal cortex) corroborates observations of memory improvement by lateral temporal cortex stimulation. We first found that the lateral temporal cortex, compared to other stimulated regions, evokes the greatest and most distributed connectivity response throughout other memory-related regions. Evoked connectivity in downstream regions is greatest when stimulating a previously identified optimal target for memory improvement, bordering white matter at the rostrocaudal center of the middle temporal gyrus. Evoked connectivity corroborates other biomarkers of memory improvement by closed-loop stimulation, including increased resting-state functional connectivity between stimulated and recorded sites and increased modulation of oscillatory power. These results provide insight into the network mechanisms of stimulation for memory and suggest that evoked connectivity can more broadly predict the functional effects of closed-loop stimulation to prospectively guide targeting and parameter selection.
Subgroup analyses from the phase 3 PANOVA-3 trial of tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma: Efficacy and safety by sex, age, and body mass index (BMI).
Babiker, Hani M., Macarulla, Teresa, Philip, Philip Agop, Ueno, Makoto, Newton, Herbert B. , Shroff, Rachna T. , Senellart, Hélène, Brenner, Warren, Matrana, Marc Ryan, Lou, E M Saiz, Kundranda, Madappa N. , Jiang, Yixing , Cutsem, Eric Van, Seufferlein, Thomas, Picozzi, Vincent J. , Babiker, Hani M. , Macarulla, Teresa , Dragovich, Tomislav , Matrana, Marc , Cutsem, Eric Van , Seufferlein, Thomas

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 707-707

10.1200/jco.2026.44.2_suppl.707 Get It

707 Background: Due to insufficient data, therapy for unresectable, locally advanced pancreatic adenocarcinoma (LAPAC) is based on trials in metastatic disease, and outcomes remain poor. TTFields disrupt cancer cell division using alternating low-frequency electric fields delivered externally by a portable device. In the phase 3 PANOVA-3 trial (NCT03377491), TTFields with gemcitabine/nab-paclitaxel (GnP) significantly improved overall survival (OS; HR 0.82) and pain-free survival (HR 0.74) vs GnP in patients with unresectable LAPAC. Methods: In PANOVA-3, patients with newly diagnosed LAPAC were randomized 1:1 to receive GnP with or without concomitant TTFields. Kaplan-Meier methodology was used for time-to-event analyses. Response evaluations were based on RECIST V1.1. OS, pain-free survival, and safety were analyzed post-hoc in subgroups based on sex (male, female), age ( < 65, ≥65 years), and BMI (<25, ≥25 kg/m 2 for efficacy; ≤20, 20–25, 25–30, ≥30 kg/m 2 for safety). Differences between treatment arms were compared using the log-rank test. Results: Efficacy outcomes are shown in the table. TTFields significantly extended pain-free survival in females and patients ≥65 years. Device-related adverse events (AEs) were comparable between sexes, older and younger patients, and across BMI ranges. Some device-related skin adverse events occurred more frequently in females (e.g. dermatitis, 33.1% vs 22.7%; rash 21.8% vs 13.5%, females vs males, respectively); others occurred more often in males (e.g. maculo-papular rash, 9.8% vs 14.2%; erythema, 9% vs 12.1%, females vs males, respectively). Dermatitis and pruritus had a higher incidence in the BMI ≥30 kg/m 2 subgroup (38.5%), whereas patients with BMI <30 kg/m 2 did not show noticeable differences in device-related AEs. Skin irritation (11.5% vs 5.5%) and skin reactions (8.5% vs 2.8%) were more common in patients ≥65 years than patients <65 years. Conclusions: Median OS and pain-free survival in these post-hoc subgroup analyses are generally consistent with the overall analysis, supporting use of TTFields with GnP in unresectable LAPAC. No new safety concerns were noted; observations were consistent with the general PANOVA-3 population. Clinical trial information: NCT03377491 . Survival outcomes for the subgroup analyses. Median OS, months TTFields + GnP GnP P value Age<65 years≥65 years 18.6 (n=113)15.4 (n=172) 16.0 (n=114)12.9 (n=172) 0.2060.061 SexFemaleMale 16.8 (n=138)15.7 (n=147) 14.5 (n=161)13.4 (n=125) 0.1140.145 BMI<25≥25 16.7 (n=166)16.2 (n=117) 14.2 (n=174)14.5 (n=108) 0.1550.105 Median pain-free survival, months Age<65 years≥65 years 16.5 (n=113)13.1 (n=172) 9.2 (n=114)8.3 (n=172) 0.4070.035 SexFemaleMale 16.5 (n=138)15.2 (n=147) 8.3 (n=161)9.3 (n=125) 0.0260.478 BMI<25≥25 16.6 (n=166)14.7 (n=117) 9.1 (n=174)8.3 (n=108) 0.1170.088